Marqués, M., Tranchant, R., Risa-Ebrí, B., Suárez-Solís, M. L., Fernández, L. C., Carrillo-de-Santa-Pau, E., ... & Blum, Y. (2020). Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Research.

https://cancerres.aacrjournals.org/content/early/2020/01/04/0008-5472.CAN-19-1633.short
* Selumetinib, PD0325901 from Axon Medchem  

Stutvoet, T. S., Kol, A., de Vries, E. G., de Bruyn, M., Fehrmann, R. S., Terwisscha van Scheltinga, A. G., & de Jong, S. (2019). MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells. The Journal of pathology, 249(1), 52-64.

Caumanns, J. J., van Wijngaarden, A., Kol, A., Meersma, G. J., Jalving, M., Bernards, R., ... & de Jong, S. (2019). Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. Cancer letters, 461, 102-111.
https://www.sciencedirect.com/science/article/pii/S0304383519304008
*AZD8055, GDC0941, Selumetinib and MLN0128 from Axon Medchem

de Boer, H. R., Pool, M., Joosten, E., Everts, M., Samplonius, D. F., Helfrich, W., ... & de Vries, E. G. (2019). Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 38(9), 1477-1488.
https://d-nb.info/1171695896/34
https://www.nature.com/articles/s41388-018-0522-7
* Erlotinib, Gefitinib, and AZD6244 from Axon Medchem 

Furlan, T., Khalid, S., Nguyen, A. V., Günther, J., & Troppmair, J. (2018). The oxidoreductase p66Shc acts as tumor suppressor in BRAFV 600E‐transformed cells. Molecular oncology, 12(6), 869-882.
https://febs.onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12199


Bosma, N. A., Singla, A. K., Downey, C. M., & Jirik, F. R. (2014). Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice. Oncoscience, 1(12), 821.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303890/  

Costales, A.Q., Huang, S., Jin, J.X., Liu, Z., Pecchi, S., Poon, D., Tellew, J. and Zhang, Q., Novartis AG, 2014. Compounds and compositions as protein kinase inhibitors. U.S. Patent 8,859,548.
https://patents.google.com/patent/US8859548/en
* PD-0325901, PD-184352, SL-032, LY294002, PI-103, PIK75, PIK90, GDC0941, BEZ235, AS252424, TGX-221 and AZD6244 from Axon Medchem

Costales, A.Q., Huang, S., Jin, J.X., Liu, Z., Pecchi, S., Poon, D. and Tellew, J., IRM LLC and Novartis AG, 2013. Compounds and compositions as protein kinase inhibitors. U.S. Patent 8,563,553.
https://patents.google.com/patent/US8563553B2/en
https://patents.google.com/patent/US8242260B2/en
* PD-0325901, PD-184352, SL-032, LY294002, PI-103, PIK75, PIK90, GDC0941, BEZ235, AS252424, TGX-221 and AZD6244 from Axon Medchem

Madera, A.M., Poon, D. and Smith, A., Novartis AG, 2013. Heteroaryl compounds and compositions as protein kinase inhibitors. U.S. Patent Application 13/805,793.
https://patents.google.com/patent/US20130096149A1/en
* PD0325901, PD184352, Sl327, LY294002, PI-103, PIK75, PIK90, GDC0941, AS-252424, TGX221, AZD6244 from Axon Medchem